CSL Ltd Annual Report 2020

Strong relationships with communities – especially healthcare providers, patient support communities and areas in which we operate – are critical to delivering on our promise. More than that, these relationships keep us connected to the evolving needs of patients and other stakeholders, so we can better support them, including with improved medicines and advocacy programs. Our approach CSL’s approach to community support is guided by our Code of Responsible Business Practice and supplemented by our Global Community Contributions Policy. The policy applies to all CSL businesses and employees and is intended to be implemented to guide decision-making and management of any form of community contribution, financial or by other means. The core of the policy is our community contributions framework, which sets out our key focus areas of support. Support for patient communities – Enhancing quality of life for patients in the conditions our therapies treat – Improving access to our biological medicines Aligns with CSL’s Values of Patient Focus and Integrity. Supports CSL’s Patient and Public Health and Focus strategic objectives by improving patient outcomes. Support for biomedical communities – Advancing knowledge in medical and scientific communities – Fostering the next generation of medical researchers Aligns with CSL’s Values of Innovation and Collaboration. Supports CSL’s Innovation strategic objective by fuelling new breakthroughs, enhancing scientific knowledge and building capability and capacity. Support for local communities – Supporting community efforts where we live and work – Supporting communities in times of emergency Aligns with CSL’s Value of Superior Performance. Supports CSL’s People and Culture strategic objective by creating an environment that employees feel proud to performwithin. Collaborative relationships with communities is an important part of our commitment to advance scientific knowledge and foster the next generation of medical researchers, as well as enhance the quality of life for patients and improve access to our medicines. In 2019/20, CSL contributed US$38.7 million to patient, biomedical and local communities, reflecting our commitment to nurturing communities in which we work and live. 60% 37% to patient communities to biomedical communities 3% to local communities US$38.7 million in community contributions CSL Limited Annual Report 2020 48 Our Communities 11